Founded in 1978 by brothers Peter and Aidan O'Boyle, Aalto Bio Reagents Ltd. ("Aalto Bio Reagents") is a leading provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. The company is particularly focused on rare tropical diseases including the zika, chikungunya and dengue virus.

Based in Dublin, it is an almost-fully export business and its customer base includes leading diagnostics and lifesciences companies across Europe, the US and Asia. To facilitate the retirement of Aalto Bio Reagents' founders, Pegasus Capital identified a new management team and advised on a management buy-in transaction.

www.aaltobioreagents.com